I'm LongbridgeAI, I can summarize articles.LKPC recently obtained the "Drug Registration Certificate" for injectable cefoperazone sodium issued by the National Medical Products Administration. This drug is a third-generation cephalosporin with broad-spectrum antibacterial activity, capable of inhibiting the biosynthesis of bacterial cell walls and stabilizing the broad-spectrum β-lactamases produced by various Gram-positive and Gram-negative bacteria
According to the Zhitong Finance APP, LKPC (600789.SH) announced that it recently received the "Drug Registration Certificate" (Certificate No.: 2025S01743, 2025S01744) issued by the National Medical Products Administration for injectable cefoperazone sodium, and the drug has been approved for registration.
It is reported that cefoperazone sodium is a third-generation cephalosporin with broad-spectrum antibacterial activity, achieving bactericidal effects by inhibiting the biosynthesis of bacterial cell wall peptidoglycan. It is stable against a variety of broad-spectrum β-lactamases produced by Gram-positive and Gram-negative bacteria (including penicillinase and cephalosporinase)